Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05096689
Other study ID # H-21017621
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date October 1, 2024

Study information

Verified date November 2021
Source Children's Fractures Interest Group, Denmark
Contact Morten J Andersen, MD
Phone 004538681479
Email mortenjonandersen@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The diagnosis of LHCF is complicated by radiographic inability to show the full extent of the injury into the chondral (unossified) epiphysis. MRI gives a perfect view of these fractures. The safety and feasibility of non-operative treatment based on MRI findings in children with elbow fractures has not been investigated in a Danish setting. If safe and feasible, the use of MRI could dramatically lower the need for surgery in children with LHCF.


Description:

The treatment of LHCF has historically most often been surgical with open reduction and fixation. The diagnosis of LHCF is complicated by radiographic inability to show the full extent of the injury into the unossified chondral epiphysis and therefore physicians often opt for open surgical treatment. MRI; however, gives a perfect view of these fractures. This project investigates the safety and feasibility of non-operative treatment of LHCF based on MRI performed without sedation or anesthesia and seeks to dramatically lower the need for surgery. Objectives are to describe functional outcome, radiological healing, secondary fracture displacement and any complications after two years. The investigators hypothesize that undisplaced and minimally displaced LHCF can be treated non-operatively based on MRI findings with good functional outcomes after two years. A cohort study design is used to follow 50 children with LHCF.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 1, 2024
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Years to 13 Years
Eligibility Inclusion Criteria: - Diagnosis of acute Lateral humeral condyle fracture - Fracture <5 days old - Fracture with <5 mm of displacement on plain radiographs - Parental informed consent obtained Exclusion Criteria: - Contraindication(s) to performing an MRI - Unable to participate in follow-up - Existing bone pathology - Previous ipsilateral elbow fracture

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MRI
Magnetic Resonance Imaging

Locations

Country Name City State
Denmark Copenhagen University Hospital - Herlev and Gentofte Herlev Capital Region

Sponsors (1)

Lead Sponsor Collaborator
Children's Fractures Interest Group, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mayo Elbow Performance Score (MEPS) MEPS consists of three domains; pain, elbow range of motion (ROM) and stability. The total score ranges from 0-100 with higher scores indicating better function. If the total score ranges between 75 and 100, the result is good (satisfactory); 50-74, fair (acceptable); <50, poor (unsatisfactory). 2 years
Secondary MRI results Proportion of successful MRIs defined as a completed scan with an image quality that is useful for analysis by the radiologist.
MRI findings. Song classification based on MRI. Scan length (minutes). Any discomforts for the child during the scan.
2 weeks
Secondary Radiographic results Injury radiographs and subsequent radiographs during FU will be read and described by a senior orthopedic surgeon. 2 years
Secondary Secondary fracture displacement Any secondary displacement and amount of radiographic displacement (mm) is recorded. 2 years
Secondary Pain scale (age <5 years) To quantify pain in the patient age <5 years, the Face, Legs, Activity, Cry, Consolability Scale (FLACC). To quantify pain behaviors in children who may not be able to verbalize the presence or severity of pain FLACC provides a simple framework. The child is observed for at least 2-5 minutes. Legs and body are observed uncovered. Activity is observed and body is assessed for tenseness and tone.
Assessment of Behavioural Score: 0 = Relaxed and comfortable. 1-3 = Mild discomfort. 4-6 = Moderate pain. 7-10 = Severe discomfort/pain.
2 years
Secondary Pain scale (age >4 years) To quantify pain in the patient >4 years, Faces Pain Scale - Revised (FPS-R) is applied.
The Faces Pain Scale - Revised (FPS-R) is used to quantify pain in children above four years of age. It is a self-report measure of pain intensity developed for children. It was adapted from the Faces Pain Scale to make it possible to score the sensation of pain on a 0-to-10 metric. The scale shows a close linear relationship with visual analog pain scales (VAS) across the age range of 4-16 years.
FPS-R is easy to administer and requires no equipment except for the photocopied faces. The child is asked to point to the face that shows how much pain the child is in at that moment. Faces are scored 0-10 so 0 equals no pain and 10 equals very much pain.
2 years
Secondary Pain scale (age >8 years) A visual analogue scale (VAS) is used to quantify pain in children age 8 and above. VAS has been extensively investigated in quantifying pain in older children. The child is asked to put a mark on the line corresponding to the child's pain at that moment. A mark to the far left equals no pain and a mark to the far right equals worst possible pain. The line is 10 cm long and the child's mark is measured from left to right in cm with one decimal e.g., 3.4 cm equaling a VAS of 3.4. If the child cannot cooperate to using VAS, FPS-R is used instead. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05773352 - Perform® Humeral System - Fracture Study (PFX)
Not yet recruiting NCT03196674 - The Effect of Controlled Feedback on the Rehabilitation of Individuals With Disability Due to Stiff Shoulder Following Trauma N/A
Recruiting NCT05802238 - Efficacy of Tranexamic Acid (TXA) in Humerus ORIF Phase 2